# Dietary β-1,3/1,6-Glucan from Baker’s Yeast Supports Upper Respiratory Mucosal Immune Health in Healthy Adults: Evidence from a Randomized, Double-Blind, Placebo-Controlled Trial

**Authors:** Takashi Kanno, Ken-Ichi Ishibashi, Shota Kajiyama, Takanori Ikawa, Taiki Morita, Kenta Murata, Shuu Imai, Machiko Nishioka, Yoshiyuki Adachi

PMC · DOI: 10.3390/nu18060961 · Nutrients · 2026-03-18

## TL;DR

A study found that a dietary supplement from baker's yeast may support upper respiratory immune health in healthy adults.

## Contribution

The study provides clinical evidence linking dietary β-1,3/1,6-glucan to improved upper respiratory mucosal immune health.

## Key findings

- SC-BG increased CD80 expression in dendritic cells in vitro.
- SC-BG intake attenuated declines in s-IgA levels and increased salivary lysozyme concentrations.
- Participants receiving SC-BG reported fewer upper respiratory tract symptoms.

## Abstract

Background/Objective: Dietary polysaccharides are increasingly recognized as functional nutritional components that support human health through modulation of immune function. However, clinical evidence linking their intake to site-specific upper respiratory mucosal immune health in humans remains limited. This study investigated whether dietary β-1,3/1,6-glucan (SC-BG) from baker’s yeast may support upper respiratory mucosal immune health in healthy adults. Methods: Following in vitro assays on human dendritic cells (DCs), a randomized, double-blind, placebo-controlled parallel-group trial was performed in healthy adults (18–69 years) who consumed either SC-BG or placebo capsules for 12 weeks in Japan. The primary outcome was circulating DC activation. Secondary outcomes were mucosal immune markers including secretory immunoglobulin A (s-IgA) and lysozymes from site-specific mucosal swabs (posterior oropharyngeal wall/nasopharynx) and salivar, and self-perceived upper respiratory tract symptoms. Results: SC-BG increased CD80 expression in DCs in vitro. In the clinical trial, 40 participants were randomized (n = 20 per group), and 39 (SC-BG: n = 19, placebo: n = 20) were analyzed. At week 8, the SC-BG group showed higher cDC1 CD80 expression than placebo. SC-BG intake also attenuated declines in s-IgA levels in the posterior oropharyngeal wall and nasopharynx and increased salivary lysozyme concentrations. Participants receiving SC-BG reported fewer cumulative days with upper respiratory tract-related local and systemic symptoms. No test food-related adverse events were observed. Conclusions: These findings provide preliminary clinical and mechanistic observations suggesting that dietary SC-BG may enhance circulating cDC1 activation and may help support upper respiratory local mucosal immune health in healthy adults, highlighting the potential of dietary polysaccharides as functional nutritional strategies for maintaining immune resilience.

## Linked entities

- **Proteins:** CD80 (CD80 molecule), SIGA (sigma factor A), lysozyme (lysozyme 1-like)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, LYZ (lysozyme) [NCBI Gene 4069] {aka AMYLD5, LYZF1, LZM}
- **Chemicals:** beta-1,3/1,6-Glucan (MESH:C033671), SC-BG (MESH:C039841), polysaccharides (MESH:D011134)
- **Species:** Homo sapiens (human, species) [taxon 9606], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13028741/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13028741/full.md

## References

49 references — full list in the complete paper: https://tomesphere.com/paper/PMC13028741/full.md

---
Source: https://tomesphere.com/paper/PMC13028741